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Duchenne muscular dystrophy (DMD; OMIM #310200) is an
X-linked recessive muscle-wasting disease, characterized by progres-
sive weakening of skeletal, respiratory, and cardiac muscle followed
by necrosis and ﬁbrosis. DMD affects 1:4,087 live male births and
is associated with delayed motor milestones.1 DMD is caused by ab-
sent or reduced levels of the dystrophin protein, which plays an
important role in the stabilization of sarcolemma. In the absence of
dystrophin, muscle strength steadily declines in the ﬁrst decade
of life, accompanied by progressive degeneration and regeneration
of muscle ﬁbers and their replacement by fat and connective tissue.2
Lack of dystrophin affects as well the cardiac muscle and the dia-
phragm, resulting in respiratory and heart failure and premature
death.
DMD occurs as a result of mutations in the DMD gene that lead
to premature termination of translation. The most frequent muta-
tions are exonic deletions and duplications that induce a frameshift
in the protein-coding sequence.3 Skipping of in-frame mutated
exons and deletions by antisense oligonucleotides (AONs) has
long been considered a promising therapeutic strategy for DMD.
This strategy aims at artiﬁcially inducing favorable exclusion of
mutated/out-of-frame exons to restore the correct reading frame.4Molecul
This is an open access article under the CC BY-NThe exciting prospect of an effective AON-based exon skipping
therapy was raised by promising data from early clinical trials
that were, however, not conﬁrmed by double-blind, placebo-
controlled phase IIb and III trials, which failed to meet efﬁcacy end-
points.5 Independently from its efﬁcacy, AON-based exon skipping
can target only a limited number of mutations: skipping of exon 51,
which could restore a correct reading frame in the largest propor-
tion of DMD mutations, would be applicable to just 10% of
DMD patients.6,7 Moreover, this and similar treatments are not
applicable to out-of-frame mutations and are of limited efﬁcacy
for exon duplications,8,9 therefore requiring a multi-exon skipping
approach.10
Among the reported DMD mutations, duplications represent a
distinct group accounting for 10%–15% of those reported in the
Leiden database,2 although their incidence may be higher,11 Duplica-
tions have been generally neglected by therapeutic approaches. Wein
et al.12 recently reported a successful attempt at inducing out-of-
frame skipping of exon 2, causing an alternative translation initiation
in exon 6 and leading to expression of a functional N-truncated dys-
trophin. These results support a potential therapeutic approach for
patients with mutations within the 50 exons of DMD, but it would
be ineffective for all the other duplications.
There is no deﬁnitive cure for DMD, and for a long time the
only treatment option has been corticosteroid administration, a
palliative management associated with many side effects. However,
two drugs have recently obtained conditional approval in Europear Therapy: Nucleic Acids Vol. 7 June 2017 ª 2017 The Author(s). 11
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. CGHProfile of DMDExon 2 Duplications and
CRISPR Design
(A) Breakpoint analysis of DMD exon 2 duplications from
different cohorts (Cochin, red; Bovolenta et al.,29,30 purple,
DelGaudio et al.,31 green; White et al.,32 turquoise) allowed
us to identify the minimal common duplicated region (light
blue shade); (B) Diagram representing the 10 kb of the
minimal common duplicated region and the position and
orientation of the gRNAs (orange) designed with ZiFiT
website in respect to the exon 2 of the DMD gene (green).
The asterisks (*) indicate the mutation of the two patients
tested in the present study.
Molecular Therapy: Nucleic Acids(Ataluren, a read-through drug for premature stop mutations)13 and
the United States (Eteplirsen, an antisense molecule to restore the
open reading frame in patients with mutations correctable by skip-
ping exon 51).14
Genome editing technology uses synthetic nucleases to introduce
targeted modiﬁcation at speciﬁc loci in the genome by exploiting
the endogenous cellular DNA repair mechanisms. These engineered
enzymes are commonly based on zinc ﬁnger nucleases (ZFNs),15
transcription activator-like effector nucleases (TALENs),16 meganu-
cleases,17 and, lately, the RNA-guided clustered regularly interspaced
short palindromic repeat (CRISPR)/Cas9 system.18 These tools have
been used to create new animal models19–21 and, recently, in vitro
and in vivo therapeutic strategies for DMD22–25 aimed at restoring
disrupted reading frames by deleting instead of skipping mutated/
out-of-frame exons. Compared to AON-mediated exon skipping,
which involves repeated injection of the therapeutic molecules with
toxicity and variable tissue uptake,26,27 the exon deletion strategywould
require only one administration of the gene-editing system to achieve
full exclusion of the targeted exon. Restoration of the reading frame
for some duplication by excising one copy of the duplicated exon
could permit expression of a normal dystrophin transcript, as recently
demonstrated for amulti-exonic duplication of 139 kb28 and allow syn-
thesis of a normal dystrophin isoform as compared to the restoration of
the reading frame around themore commondeletions that can generate
a less severe, Becker muscular dystrophy (BMD)-like phenotype.
We report a CRISPR/Cas9 strategy to remove the most frequent
duplication in the DMD gene, applicable to all patients with exon 2
duplications. The deletion restores synthesis of wild-type dystrophin
at the transcriptional and protein level, adding relevant information12 Molecular Therapy: Nucleic Acids Vol. 7 June 2017on the efﬁciency of the gene-editing approach
and the correct localization of the resulting
protein.
RESULTS
Strategy for the Correction of Duplications in
DMD and gRNA Rational Design
Our strategy to target duplications relies on
the hypothesis that a single guide RNA (gRNA)designed over a tandem duplicated region will cut twice, leading
to the deletion of the region between the two double-strand
breaks (DSBs), thereby removing the duplication. This approach
has been independently validated by the Cohn lab (University of
Toronto) to remove a duplication of the exons 18–30 in the
DMD gene.28
To identify editing targets able to correct the DMD duplication of the
exon 2 (dup2) in all patients bearing this type of mutation, we
collected DNA from eight patients and characterized the extension
of the copy number variation with the DMD-CGH array.29 Data
from ten more patients were collected from the literature29–32 and
aligned with the other duplications analyzed in order to identify a
region shared among all the patients studied (Figure 1A). Interest-
ingly, we identiﬁed duplicated regions spanning 25 to 286 kb with
no common breakpoints.
A duplicated minimum common region (MCR) of about 10 kb was
uploaded in ZiFiT and gRNAs of 18 nucleotides were selected based
on the available guidelines and on the smallest number of potential off
targets with a maximum of two mismatches. We also designed two
gRNAs (one of which was 19 nt) targeting the coding sequence of
the exon 2 in order to conﬁrm the evidence that shifting the reading
frame in the early codons should trigger the translational restart at
exon 6 as previously demonstrated by an exon skipping approach
(Figure 1B).12
gRNAs were named according to the following code: cr (crispr),
DMD, int (intron), or ex (exon) 2 and numbered from 1 to 6 (the
crDMD notation have been omitted in Figures 2E, 2F, and 3 to limit
redundancy). Repeated regions and functional splicing sequences
Figure 2. Detection of Deletion and Inversions after Transfection of Two gRNAs in Myogenic Cells
(A) Schematic representation of the 5.6-kb deletion created by transfecting the crDMDint2.1 and int2.6 gRNAs in a control myogenic cell line. The primers used to amplify
across the deletion breakpoint and the wild-type sequence are shown as colored arrows: red, forward common primer; blue, wild-type-specific reverse primer; green,
deletion-specific reverse primer. (B) PCR amplification and sequencing of the wild-type and deleted products. The PCR amplification revealed a product corresponding to
the deleted sequence of about 1.1 kb only in treated cells (left panel, first lane), whereas the amplification of the wild-type sequence was obtained in both treated and
untreated cells with a reduced amplification evident in treated cells. Sequence analysis of the deleted product showed the presence of two products with the only
difference of a thymine at the breakpoint causing a shifting starting from the shaded column (right panel). (C and D) Schemes representing the strategies used to amplify
the deletions and inversions caused by two gRNAs. The same forward primer located upstream the first gRNA binding site (F1) was used in both approaches in
combination with a reverse one downstream to the second gRNA binding site for deletions detection (C) and a second forward primer (F2) upstream the second gRNA
binding site for inversions amplification (D). (E) PCR products resulting from the amplification of the deletion breakpoints. The combination of the gRNAs used is reported
above the image, whereas the expected products size in base pairs is displayed below it. All the bands where excised and sequenced or directly sequenced (Figure S2).
(F) PCR products resulting from the amplification of the inversions breakpoints. The combination of the gRNAs used is reported above the image, whereas the expected
products size in base pairs is displayed below it. All the bands where excised and sequenced or directly sequenced (Figure S2). A PCR product resulting from the
nonspecific amplification was found in the second lane (i2.1/i2.3, upper band). An unexpected product was found in the fourth lane upon treatment with i2.1 and i2.6;
sequencing reported the presence of a complex rearrangement and coexistence of an inversion and deletion between the two gRNAs (Figure S2). T, treated; UT,
untreated.
www.moleculartherapy.orgwere excluded from the design. All gRNA sequences were cloned in
the MLM3636 plasmid backbone (Table S1).
Testing of gRNAs Activity by Plasmid Transfection in HEK293T
and Myogenic Cell Lines
To validate the ability of gRNAs to induce DSBs, we transfected each
gRNA and the Staphylococcus pyogenes’s Cas9 (spCas9, JDS246) in
HEK293T cells and performed the T7E1 assay. Interestingly, the PCR
system amplifying across the gRNA crDMDint2.1 and crDMDint2.2
regions incorporates a simple tandem repeat (TG) that creates a hetero-duplex that is cleaved into two fragments when digested with the T7E1
enzyme (Figure S1).
To test the gRNAs in myogenic cells, we obtained primary myoblasts
from two DMD patients with large duplications of 137 and 263 Kb,
respectively, encompassing the exon 2 (Figure 1A; #994 and #515).
These cells have been immortalized as previously described.33 Due
to low transfection efﬁciency (<20%, data not shown) of myoblasts,
we chose to test the presence of deletions caused by two gRNAs, as
they can be easily discriminated from the wild-type sequences. Hence,Molecular Therapy: Nucleic Acids Vol. 7 June 2017 13
Figure 3. DNA, RNA, and Protein Expression Analysis after Infection with LentiCRISPRv2
(A) Histograms reporting the genomic analysis by real-time PCRof the duplicated sequence. Transduced cells present reduction of the duplication in respect to untreated cells
(UT) set to 1.Wild-type cells were analyzed as positive control. (B) RT-PCRwas performedwith primers designed on the exon 1 and 4. Onemicroliter of the displayed PCRwas
loadedonahigh-sensitivity DNAchip and runon theBioanalyser 2100 (Agilent). Quantification of the peakobtainedwasperformedcalculating the ratio of the area of the normal
transcript and the sum of the area of normal and duplicated transcript multiplied for 100 and normalized by setting the untreated (UT) as one. *p < 0.05 (Kruskal-Wallis test with
post hoc Mann-Whitney test from three independent experiments). ns, not significant. (C) Western blot from treated and untreated myotubes of patient 994 and 515, with
antibodies against dystrophin, Cas9 and a-actinin as loading normalizer. The amount of dystrophin was normalized to that of actinin by densitometric analysis. WT, wild-type.
(D) Immunocytochemistry of dystrophin (red) and nuclei (blue) inmyotubes frompatient 994. Scale bar, 1mm.All error bars represent theSD for three independent experiments.
Molecular Therapy: Nucleic Acidswe co-transfected Cas9 and different combinations of two gRNA in a
wild-type myogenic cell line and tested the ability of the two gRNAs to
delete a genomic region. We ﬁrst tested the two gRNA crDMDint2.1
and crDMDint2.6 and detected a deletion of 5.6 kb resulting in
about a 20% of reduction in the ampliﬁcation of the wild-type region
in treated cells when compared to untreated cells (Figure 2A). The
PCR product corresponding to the deleted sequence was only detect-
able in treated cells. Sequencing of the latter revealed the coexistence
of two products differing from each other for the insertion of one
thymine at the breakpoint (Figure 2B).
As previously reported by Kraft et al.,34 the use of two synthetic
gRNAs targeting two different positions of the same chromosome in-
duces deletions, inversions and duplications through non-homolo-
gous end joining (NHEJ). Hence, we tested the occurrence of deletions
and inversions by speciﬁcally designed PCR (Figures 2C and 2D)
amplifying and sequencing the expected deletions and inversions of
different range between the target sites of the tested gRNAs (Figures
2E and 2F). A representation of deletions and inversions obtained14 Molecular Therapy: Nucleic Acids Vol. 7 June 2017with two gRNAs and the sequence of the respective breakpoints is
available in Figure S2.
Overall, ﬁve out of seven of our gRNAs resulted to have activity in
HEK293T cells (Figure S1) and were able to introduce deletions
(80%) and inversions (72%) when used in couples in a myogenic
cell line (Figure 2).
Targeted Removal of a Large Duplication in Myogenic Cells by
Lentiviral Delivery of CRISPR/Cas9 without Selection
In order to increase the efﬁcacy and maximize our results in cell lines,
we cloned the more efﬁcient gRNAs in the LentiCRISPRv2 vector
(Addgene Plasmid #52961).35 We did not select the infected cells
by antibiotics resistance as the immortalization process takes advan-
tage of two lentiviruses and one shares the puromycin resistance
also present in the LentiCRISPRv2 vector. We analyzed vector copy
number (VCN) 72 hr after transduction at a multiplicity of infection
(MOI) of 20 (Table 1). #515 and #994 cells received an average of
0.6 and 2.7 copies of LentiCRISPRv2, respectively.
Table 1. VCN Analysis
Cells LV.CRISPR VCN (Total) VCN (LV.CRISPR)
515 — 3.4 —
994 — 3.6 —
515 LV_int2.1 4.1 0.7
515 LV_int2.6 3.8 0.4
515 LV_ex2.1 4.2 0.8
994 LV_int2.1 6.6 3
994 LV_int2.6 6.2 2.6
994 LV_ex2.1 6.2 2.6
LV, lentivirus.
www.moleculartherapy.orgTo quantify the deletions of the duplicated region and indirectly
the wild-type alleles created by the editing, we analyzed the genomic
region targeted by our approach versus a region in intron 67 of
the DMD gene by real-time PCR. We detected the highest rate of
deletions in 994 cells treated with LV_int2.1 (about the 13%),
whereas no deletions at all were revealed in 515 cells transduced
with LV_Ex2.1 (Figure 3A).
We then investigated the presence of inversion events by amplifying
the region targeted by the gRNAs with only one primer close to the
target region (Figure S3). We obtained no evidence of inversion event
despite 45 cycles of PCR ampliﬁcation (data not shown).
In order to better investigate dystrophin expression, we induced
myoblast differentiation to myotubes. RNA analysis revealed an
increased ratio between wild-type/duplicated transcripts ranging
from 1.5 to about 4-fold in cells transduced by LentiCRISPRv2 (Fig-
ure 3B). Western blot analysis showed restoration of wild-type dys-
trophin in #994 cells transduced with LV_int2.1 (11%) and LV_int2.6
(7%) when compared to wild-type (Figure 3C), whereas #515 cells
did not show any labeling; this is probably due to the low rate of trans-
duction in #515 cells with VCN spanning from 0.4 to 0.8 while being
around 3 in #994 cells.
Immunocytochemistry showed intense expression and correct local-
ization of dystrophin in clustered myotubes in differentiated #994
cells infected with LV_int2.1 and LV_int2.6, even though these repre-
sented only a 5% of total cell population (Figure 3D).
We then investigated the on-target versus off-target activity of gRNA
crDMDint2.1, which showed the highest activity in restoring dystro-
phin expression. We scored 73% on-target activity in 110 clones
sequenced (Figure S4, upper table) and no off-target effect by T7E1
assay (Figure S4, bottom table).
DISCUSSION
The recent development of the CRISPR/Cas9 system have brought
great excitement in the research community and new perspectives
for the treatment of several genetic diseases, and recently for DMDwith convincing data in vitro and in vivo.36–40 For these purposes,
the CRISPR/Cas9 system has been mainly exploited to remove out-
of-frame or in-frame mutated exons and restore the dystrophin
reading-frame by targeting the sequence to be removed with two
gRNAs. This approach is applicable to out-of-frame deletions and
point mutations optimistically accounting for the 85% of all muta-
tions, restoring the expression of a smaller functional protein and
converting the severe phenotype into a milder, Becker-like one, as
aimed by exon skipping approaches.41
Duplications represent the third cause of DMD among all the dystro-
phin mutations. The attempt to treat duplications has been recently
reported, in a multi-exonic duplication in the DMD gene.28 Here,
we described a strategy to correct the most frequent duplication in
the DMD gene that could be extended to all other, less frequent du-
plications, leading to the synthesis of full-length, wild-type dystro-
phin. CGH analysis allowed us to identify a minimal region that is
duplicated and shared among all the patients studied, against which
we screened gRNAs with the aim of ﬁnding a deletion strategy poten-
tially addressing all those patients (Figure 1). We used lentiviral vec-
tors to bring our gRNAs and the spCas9 in patient-derived myoblasts,
in order to maximize the efﬁciency of delivery and have both elements
in a single vector. We were able to quantify the efﬁciency of the
Cas9-induced deletions directly in treated cells without selection,
and assay the results at both transcriptional and protein expression
levels by cytochemical analysis of myotubes differentiated in vitro
from treated myoblasts. The sequence analysis of inversions and de-
letions breakpoints indicated that rearrangements caused by two
gRNAs are mostly neat and show the mutational spectrum intro-
duced by NHEJ only in few cases (Figure S2). Interestingly, we did
not detect inversions when dup2 patient’s myoblasts were treated,
backing up the concept that deletions occur more frequently than in-
versions in our system, as described elsewhere.34
Treatment of immortalized myoblasts derived from two dup2 pa-
tients resulted in the deletion of the duplication at the genomic
level (Figure 3A) and in an increased expression of wild-type dys-
trophin transcripts (Figure 3B). This expression was followed by a
detectable and correctly localized dystrophin only in the #994 cell
line (Figures 3C and 3D), which carries a smaller duplication of
137 kb, and not in the #515 cell line, which carries a larger, 263-
kb duplication, probably due to the limited transduction efﬁciency
in this cell line. Our results are concordant with those reported by
Wojtal et al.28 in terms of restoration of protein expression in
cells bearing deletions of comparable size (139 and 137 kb). We
extended the signiﬁcance of those ﬁndings by reporting the correct
localization of dystrophin at the sarcolemma in myotubes derived
from #994 cells transduced with two out of three lentiviral vectors,
despite the small number of myoblasts positive for DMD expression
(Figure 3D).
Even if we did not detect off-target activity for the best gRNA in our
hands (Figure S4, bottom table), the recent improvements in the
CRISPR design,42 speciﬁcity of the spCas943 and repertoire of Cas9Molecular Therapy: Nucleic Acids Vol. 7 June 2017 15
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opens perspectives for the clinical investigation.
In fact, by delivering Cas9 and gRNAs with adeno-associated virus
(AAV) vectors it will be possible to speciﬁcally drive the correction
of duplications to the muscles in vivo.37 It has been demonstrated
that the AAV viral genomes are lost in the regenerating dystrophic
skeletal muscle.46 This could mimic a transient expression of the
CRISPR/Cas9 system, which reduces the risk of immune response
and off-target activity while still producing stable genome modiﬁca-
tions in satellite cells that could be able to repair or restore the
muscles.37
Taken together, these data indicate that the removal of a duplication
event by Cas9-mediated genome editing is feasible with only one
gRNA directed against a duplicated intronic region (which is dupli-
cated in a relevant number of DMD patients), increasing editing
efﬁciency and reducing the risk of off-target effects. These ﬁndings
provide proof of concept for a gene-editing approach in DMD pa-
tients carrying duplications and lay out the foundation for further
research into the application such an approach in other inherited dis-
orders caused by gene duplications.
MATERIALS AND METHODS
Patients
We have studied eight DMD patients known to have duplications of
the exon 2 by multiple ligase probe ampliﬁcation (MLPA) analysis.
DNA from these patients was obtained thanks to the collaboration
with Dr. France Leturcq through the AFM-Telethon Biobank.
Myoblasts from two of these patients (ID #515 and #994), available
through the Biobank, were immortalized thanks to the collaboration
with the Institut de Myologie as previously described.33
Informed consent was obtained from all patients to conduct the study,
which was in accordance with the Helsinki Declaration. All the exper-
imental procedures were approved by Genethon.
CGH Analysis
According to manufacturer’s instructions, DNA samples were pro-
cessed andhybridized to theDMD-CGHarray as previously reported.29
The array was analyzed with the Agilent scanner and the Feature
Extraction software (v.12.0). A graphical overview and analysis of the
data were obtained using the Agilent Genomic Workbench (v.7.0).
For identifying duplications and deletions, we used the standard setup
of the ADM-2 statistical analysis provided by Genomic Workbench
software (Agilent).
The array platform and data-related information have been sub-
mitted to the online data repository Gene Expression Omnibus
(GEO, NCBI): GSE83658.
A graphical representationof theduplicationswasproducedby creating
a custom track and displaying it in UCSC Genome Browser GRCh37/16 Molecular Therapy: Nucleic Acids Vol. 7 June 2017hg19 assembly (http://genome.ucsc.edu). Ten more characterized du-
plications of the exon 2 from DMD patients were collected from the
literature27–30 and represented with a custom track (Figure 1A).
gRNA Design and Off-Target Prediction
The minimal common duplicated region shared among all the
patients was uploaded in ZiFiT (http://ziﬁt.partners.org/ZiFiT/) and
used as a template to design six truncated gRNAs47 of 18 bp and
one (crDMDex2) of 19 bp (Figure 1B). Oligos used to clone the
gRNAs are shown in the Table S1. According to the available guide-
lines48 on CRISPR design we selected and cloned into the MLM3636
backbone (Addgene number 43860) those with less than ten off-target
regions with two mismatches as predicted by ZiFiT (Figure S4).
Cell Cultures
To preliminarily screen the activity of the candidate gRNAs, we trans-
fected HEK293T cells with the Cas9 plasmid JDS246 (Addgene num-
ber 43861) and with each gRNA, using Lipofectamine2000 (Thermo
Fisher Scientiﬁc). DNA extraction (Blood & Cell Culture DNA Mini
Kit, QIAGEN) was performed 72 hr after transfection for PCR ampli-
ﬁcation and T7E1 assay.
Immortalized DMD myoblasts were maintained in Skeletal Muscle
Growth Medium (Promocell) and differentiated into myotubes for
at least 7 days in Skeletal Muscle Differentiation Medium (Promo-
cell) at 37C with 5% CO2 incubation. Transfection of spCas9 and
DMD gRNAs was performed with JetPEI (Polyplus) following man-
ufacturer’s instructions. After 72 hr, DNA was extracted to perform
PCR ampliﬁcation.
T7EI Assay
PCR amplicons for targeted and off-target genomic regions were ob-
tained by ampliﬁcation with Platinum Taq DNA Polymerase High
Fidelity (Thermo Scientiﬁc). The PCRs were carried out under the
following conditions: preheating 95C for 5 min, followed by 35
cycles of 95C for 30 s, 64C for 30 s, and 68C for 1 min 20 s.
The PCRproducts were resolved on 1.5% agarose gel and then puriﬁed
with Qiaquick PCR Puriﬁcation Kit (QIAGEN). For T7E1 cleavage
assay puriﬁed PCR products were denatured and annealed in
NEBuffer 2 (NEB) using a thermocycler. Hybridized PCR products
were digested with T7 endonuclease 1 (NEB, M0302L) for 15 min at
37C and subjected to 2% agarose gel electrophoresis. Percentage of
DNAmodiﬁcationwas calculated using the formula%DNAmodiﬁca-
tion = 100*(1-(1-fraction cleaved)1/2) reported on the NEB website
(https://www.neb.com/protocols/2014/08/11/determining-genome-
targeting-efﬁciency-using-t7-endonuclease-i). All PCR primer se-
quences are listed in Table S2.
Detection of Deletions and Inversions
The gDNA samples obtained from cells transfected with two gRNAs
were ampliﬁed with Platinum Taq DNA Polymerase High Fidelity
(Thermo Scientiﬁc). We prepared two speciﬁc PCRs with a common
forward primer upstream the ﬁrst gRNA binding site and a second
www.moleculartherapy.orgforward primer localized between the two gRNA binding sites to
detect inversions or a reverse primer downstream the second gRNA
binding site to detect inversions (Figures 2C and 2D). The PCRs
were conducted in order to detect genomic deletions and inversions
under these conditions: preheating 95C for 5 min, followed by 35 cy-
cles of 95C for 30 s, 60C for 30 s, and 68C for 40 s. Inversions were
ampliﬁed with 40 cycles.
Inversions in cells with duplication of the exon 2 were ampliﬁed with
only one forward primer upstream of the binding site of the gRNA
used. If inversions occur, the primer would bind to the wild-type
sequence in forward orientation and the inverted one in reverse
orientation (Figure S3). PCR conditions were preheating 95C for
5 min, followed by 45 cycles of 95C for 30 s, 60C for 30 s, and
68C for 40 s.
Amplicons were resolved through 1.5% agarose gel electrophoresis.
All PCR primer sequences are listed in Table S3.
Lentivirus Production, Titration, and Transduction
In order to increase the efﬁcacy and maximize our results in cell lines,
we cloned selected gRNAs in the LentiCRISPRv2 vector (Addgene
Plasmid #52961).35
Research Grade Lentiviral Vector Production
Third-generation lentiviral vectors were produced by calcium phos-
phate transient transfectionof 293T cells of the selected transfer vector,
the packaging plasmid pKLg/p.RRE, pK.REV, the vesicular stomatitis
virus glycoprotein G (VSV-G) envelope plasmid pK.G as previously
described.49
Lentiviral Vector Titration
Three hundred thousand (3  105) HCT116 cells were transduced
with serial vector dilutions in the presence of polybrene (6 mg/mL).
Genomic DNA (gDNA) was extracted 72 hr after transduction.
gDNA is extracted by using MagNaPure 96 system (Roche Diagnos-
tics, Promega) according to manufacturer’s instructions. Vector
copies per diploid genome (VCN) were quantiﬁed by quantitative
PCR (qPCR) starting from 100 ng of template gDNA using primers
(HIV sense: 50-TACTGACGCTCTCGCACC-30; HIV antisense:
50-TCTCGACGCAGGACTCG-30) and a probe FAM 50- ATCTCTC
TCCTTCTAGCCTC-30) against the packaging signal region of LVs.
Endogenous DNA amount was quantiﬁed by a primers/probe set
against the human albumin gene (ALB sense: 50 GCTGTCATCT
CTTGTGGGCTGT-30; ALB antisense: 50-ACTCATGGGAGCTGC
TGGTTC-30; ALB probe: VIC 50-CCTGTCATGCCCACACAAAT
CTCTCC-30). Copies per genome were calculated by the formula =
[ng LV/ng endogenous DNA]  [no. of LV integrations in the stan-
dard curve]. The standard curve was generated by using a plasmid
containing the appropriate sequences in cis from the vectors and
ALB gene. Vector particles were measured by HIV-1 Gag p24 antigen
immunocapture assay (PerkinElmer) according to manufacturer’s in-
structions. Vector infectivity is calculated as the ratio between titer
and particles.50Titers obtained ranged from 5.8E8 transducing units (TU)/mL to
1.1E9 TU/mL. LV_int2.1, LV_int2.6 and LV_ex2.1 were used at
MOI 20 together with 8 mg/mL of polybrene in exon 2 duplicated
myoblasts cell lines.
Quantification of Wild-Type Alleles Created after Removal of the
Exon 2 Duplication by One gRNA
Quantiﬁcation of the efﬁcacy of the gRNAs to remove the duplicated
sequence at the DNA level was performed by Real-Time PCR using
SsoFast EvaGreen Supermix (Bio-Rad) for 40 cycles and primers
designed on the minimal common duplicated region (forward
CCAAACCCATAGTCGTTCAAAT, reverse AGATGCTGCAAA
GGAAGGAA) and on intron 67 of the DMD gene as control (for-
ward GCATTTGGAAAGATTTGCTGA, reverse TGCTGGTGC
AGACTTCTCTC). Real-Time PCR was performed in triplicate in
96-well plates using 50 ng genomic DNA from wild-type, untreated,
and lentiviral transduced cells. The calculation of the fold changes
was based on the 2DDCT method (Applied Biosystems User
Bulletin #2) and results were expressed in relation to the untreated
cells set to 1.
RNA Analysis
Total RNA was isolated from myotubes three days after differentia-
tion using the RNeasy Kit (QIAGEN) and reverse-transcribed by
means of a High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems), according to the manufacturer’s instructions.
Before cDNA synthesis, RNA was treated with DNase I (Roche) and
checked for residual DNA contamination by a 55-cycle PCR.
RT-PCR of the exon 2 duplication was performed with Platinum Taq
DNA Polymerase High Fidelity (Thermo Scientiﬁc) and oligos 21F
and 448R (designed complementary to exon 1 and 4 of the DMD
muscle isoform and taken from http://dmd.nl/) and resolved on 2%
agarose gel. One microliter of the RT-PCR was loaded on high-sensi-
tivity DNA chips (Agilent) for the quantiﬁcation of the duplication
excision, which was performed calculating the ratio of the area of
the normal transcript and the sum of the area of normal and dupli-
cated transcripts multiplied for 100 and normalized by setting to
one the untreated (UT) samples. Experiments were performed in trip-
licate, mean results and SDs are shown. Signiﬁcance was evaluated by
Kruskal-Wallis test with post hocMann-Whitney test for p values less
than 0.05 considered signiﬁcant.
Western Blot and Immunofluorescence Analysis
Immortalized myoblasts seeded in 30-cm Petri dishes and differenti-
ated for 10 days were washed with cold PBS and lysed in radioimmu-
noprecipitation assay (RIPA) buffer in presence of Complete Mini
protease inhibitor mixture (Roche) for 30 min on ice. Cell lysates
were cleared and quantiﬁed.
To check the expression of dystrophin, 30 mg of protein from
myotubes was mixed with 4  NuPage LDS buffer (Invitrogen) sup-
plemented with 50 mM DTT, heated for 2 min at 85C, loaded onMolecular Therapy: Nucleic Acids Vol. 7 June 2017 17
Molecular Therapy: Nucleic AcidsNovex 3%–8% Tris-Acetate Midi Gel (Invitrogen), and electrophor-
esed at 150 V with Tris-Acetate SDS running buffer (Invitrogen)
for 70 min at room temperature. Proteins were then transferred at
45 V overnight at 4C onto polyvinylidene ﬂuoride (PVDF) mem-
branes as described above using transfer buffer with no methanol.
Membranes were blocked in Tris-buffered saline-tween (TBS-T)
(20 mM Tris, 500 mM NaCl [pH = 7.5], 0.1% Tween 20) supple-
mented with 3% (Dystrophin and Cas9) or 5% (a-actinin) non-fat
dry milk (Bio-Rad) for 1 hr at room temperature.
Membranes were incubated for 1 hr at room temperature with rabbit
polyclonal anti-Dystrophin (ab15266, Abcam), anti-CRISPR-Cas9
(ab191468, Abcam), and mouse monoclonal a-actinin (Santa Cruz
Biotechnology) antibodies, washed three times for 10 min in TBS-T,
incubated with immunopure goat anti-rabbit or rabbit anti-mouse
immunoglobulin Gs (IgGs) (Dako) conjugated to horseradish perox-
idase (HRP, 1:2,000 in TBS-T 3 or 5% milk) for 1 hr at room tem-
perature, and revealed with Pierce ECL Western Blotting Substrate
(Pierce Biotechnology). Chemiluminescence was acquired by the
ChemiDoc MP System (Bio-Rad) and quantiﬁed using ImageJ
v.1.37 (NIH image). Immortalized control myoblasts differentiated
into myotubes in vitro were used as positive control.
In vitro differentiated immortalized wild-type, #515 and #994 myo-
blasts were washed with PBS (Sigma-Aldrich), ﬁxed with 4% parafor-
maldehyde (Sigma-Aldrich) at room temperature for 10 min, and
permeabilized with ethanol 75% (Sigma-Aldrich) at room tem-
perature for 1 min. As a blocking solution, 20% fetal bovine serum
(Sigma-Aldrich) was used at room temperature for 30 min to reduce
secondary antibody background signal. The cells were subsequently
incubated overnight at 4Cwith the anti-dystrophin (NCL-DYS2No-
vocastra) primary antibody. After incubation, cells were washed with
PBS and then incubated with the 594-ﬂuorochrome conjugated sec-
ondary antibodies (Thermo Fisher) together with DAPI for nucleic
acid staining (Ibidi) for 1 hr at room temperature in PBS containing
0.2% Triton X-100. After three successive washings with PBS, dishes
were mounted using ﬂuorescent mountingmedium (Ibidi) and exam-
ined by ﬂuorescence microscopy (DMI6000B, Leica).
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Figure S1. Testing gRNAs for NHEJ indel formation in HEK293T cells: (a) schematic of the PCR systems designed to 
amplify four regions of the minimal common duplicated region (MCR). For each region the intervening gRNAs are shown 
and predicted fragments generated by the T7E1 treatment are color-coded. (b) T7E1 assay of PCR products from HEK293T 
cells transfected with MLM3636 gRNA plasmids and spCas9 (JDS246). Coloured Dots indicate the position of T7E1 
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Figure S2: Characterization of deletion and Inversion Breakpoints.  
Visualization of deletions and inversions caused by the activity of two gRNAS obtained by loading the resulting sequences 
(left panels: deletions; right panels: inversions) in UCSC Genome Browser and creating two custom tracks.  
The sequences of each gRNA are overlaid over the chromatograms and represented by an orange thick bar for the PAM 
sequence and arrowed orange bars for the binding sequences. Deletion breakpoints are represented as black arrows between 
two black bars whereas inversion is shown as colour-coded bars with arrows indicating the original orientation of the 
sequence.       
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Figure S3: Strategy to amplify inversions of the duplicated region caused by activity of a gRNA with one primer. The primer 
and the gRNA are represented as green and light blue triangles respectively. The tandem duplication is coloured in red and 






Deletions      PAM    gRNA Int2.1 
TACCTCCTTCACTGAAATAATGTTTTGCCACTTTGTCCCAGTATCATCCTTTTTTAAAAACTTCTAAGCTCATTTTAAAT WT 26.3%(29/110) 
 











TACCTCCTTCACTGAAATAATGTTTTGCCACTTT---------(133)----------------ATGTTTACTGGGTGTG    




TACCTCCTTCACTGAAATAATGTTTTGCCACTTT--TGT-CCCAGTATCATCCTTTTTTAAAAACTTCTAAGCTCATTTTAAAT insT  x41 




         Insertions:  41.8%(46/110) 
Indels 
TACCTCCTTCACTGAAATAATGTTTTGCCACTTT---C--CCCAGTATCATCCTTTTTTAAAAACTTCTAAGCTCATTTTAAAT insC delGT 
             Indels:   0.01%(1/110) 










Potential off-target site # Sequence Indels (%) Chromosome # Strand Position GENE Mismatch #1 Mismatch #2 Mismatch #3
Site Of Interest GATGATACTGGGACAAAG 72.71% DMD, intronic
Potential Off-Target site # 1 GTTGAAACTGGGACAAAG nd chr6 - 105368929 none 1:A>T 5:T>A
Potential Off-Target site # 2 GAAGATACTGGGAGAAAG nd chr2 + 217969247 none 2:A>T 13:G>C
Potential Off-Target site # 3 GATGAGACTGGGAGAAAG nd chr12 + 90417929 none 5:G>T 13:G>C
Potential Off-Target site # 4 GATGACAGTGGGACAAAG nd chr2 - 11851832 LPIN1, intronic 5:G>A 7:C>G
Potential Off-Target site # 6 GGTCACACTGGGACAAAG nd chr1 - 162675015 none 1:C>T 3:G>C 5:G>A
Potential Off-Target site # 16 GAACAGACTGGGACAAAG nd chr11 - 8381632 none 2:T>A 3:G>C 5:C>A
Potential Off-Target site # 57 GATGATACTGAGACAAAT nd chr16 - 87824358 none 10:T>C 17:A>C
Potential Off-Target site # 58 GATGATACTGGGAGAAAA nd chr17 + 60562033 TLK2, intronic 13:G>C 17:A>G
Potential Off-Target site # 59 GATGATACTGGGAGAAAA nd chr7 + 128177242 none 13:G>C 17:A>G
Potential Off-Target site # 91 GATGATACTGTGATAAAG nd chr14 + 66373651 none 10:T>G 13:T>C
Potential Off-Target site # 92 GATGATAATGGTACAAAG nd chr5 - 13605091 none 7:T>G 11:A>C
Potential Off-Target site # 93 GTTGCCACTGGGACAAAG nd chrX + 48165879 RNLP, intronic 1:T>A 4:C>A 5:C>T
Potential Off-Target site # 99 GACTCTACTGGGACAAAG nd chr11 + 23900800 none 2:C>T 3:T>G 4:C>A
Summary: Off by 0 = 1; Off by 1 = 0; 




Name Forward Reverse 
crDMDex2 ACACCGGTAAATGCACAATTTTCTAG AAAACTAGAAAATTGTGCATTTACCG 
crDMDex2.1 ACACCGTAAATGCACAATTTTCTAG AAAACTAGAAAATTGTGCATTTACG 
crDMDint2.1 ACACCGATGATACTGGGACAAAGG AAAACCTTTGTCCCAGTATCATCG 
crDMDint2.2 ACACCGTTAAGATTCGGGGACAGG AAAACCTGTCCCCGAATCTTAACG 
crDMDint2.3 ACACCGAGTGGGCTCAGTGTGGGG AAAACCCCACACTGAGCCCACTCG 
crDMDint2.4 ACACCGATAAATGATAATGGAAAG AAAACTTTCCATTATCATTTATCG 







Name Sequence Target 
1299F CTGCCTGCTTCTCATAGGACTT Minimal common region 1 
  2562R AACACGGAAGGTTTTGCTGATG 
5698F AGTTGTATGAATGTGTGTGTGCC Minimal common region 2 
  6986R TGGAATTCTGAAGCAGACAAGAGA 
6673F AATTGCTCTGAGGCAGTGCTAA Minimal common region 3 
  7915R TGTGCAGGCTTCAATCCATACT 
7555F TAAAGCCTTGGGTTTAAGGGCC 
Minimal common region 4 
8710R GTGATCCGTCCTCACTGGC 
i2.1Offchr5F CCAGCTGCCGAAGATTCAT 
Potential Off-Target site #92 chr5:13605091 
i2.1Offchr5R CATCTCCCAGAAACACAGCA 
i2.1Offchr14F ATTCAGGTCCATGGAGGCAG 
Potential Off-Target site #91 chr14:66373651 
i2.1Offchr14R  CTCTTTTCCTTCGCCCTCCC 
i2.1Offchr7F TCTCAGCTCACTGCAACCTC 
Potential Off-Target site #59 chr7:128177242 
i2.1Offchr7R TAGCCAGGATGGTCTCGATC 
i2.1OffChr17F AGCAATTCTCGTGCCTCAGC 
Potential Off-Target site #58 chr17:60562033 
i2.1OffChr17R  CACCCACCACCAAGCTCAG 
i2.1Offchr16F  AGCTGCTCTTTGGGGTCTTC 
Potential Off-Target site #57 chr16:87824358 
i2.1Offchr16R  GCCTTGTGATCCACTCCCAA 
i2.1Offchr2aF TACCCCAGCAAGGATCCAGA 
Potential Off-Target site #04 chr2:11851832 
i2.1Offchr2aR CAGAGCAGTGTGAGAGCAGT 
i2.1Offchr12F TGGGTGAGGATGGAGAGGAG 
Potential Off-Target site #03 chr12:90417929 
i2.1Offchr12R  ATCCGGGCCCTATGCTATCT 
i2.1Offchr2bF TATGGCAGTAGGGGCTGGAT 
Potential Off-Target site #02 chr2:217969247 
i2.1Offchr2bR TCTCTCTGGCTTAGACTTCCA 
i2.1Offchr6F CAGCCTAGGTGACAGAGCAA 
Potential Off-Target site #01 chr6:105368929 
i2.1Offchr6R GTTGCACTGAGCCGAAGATG 
i2.1Offchr1F  GAGACCGTGGTTCCTGTAGC 
Potential Off-Target site #06 chr1:162675015 
i2.1Offchr1R TAGAGTTGCCCCCTGATCCA 
i2.1OffchrXF  CGACCTGCCTCACATACACT 
Potential Off-Target site #93 chrX:48165879 
i2.1OffchrXR TAACCCGAGATCCAGGCATG 
i2.1Offchr11aF AAGGGCCTGACACTTTCCTG 
Potential Off-Target site #16 chr11:8381632 
i2.1Offchr11aR CCTGAACCCAACAAGACCCT 
i2.1Offchr11bF AGCCAATTTTCCTCACACCA 
Potential Off-Target site #99 chr11:23900800 
i2.1Offchr11bR GTAGCTGGGACTACAGGCAC 
 





Name Sequence Name Sequence Target 
1861F TCTGTTAAAGCAGGCACATTGC 
2194F GTTTGATGCCAAGAAGGTAGCC i2.1/i2.2 inversion 
2666R GTGTCCTGGTTTTCAGTGCATT i2.1/i2.2 deletion 
1861F TCTGTTAAAGCAGGCACATTGC 
5698F AGTTGTATGAATGTGTGTGTGCC i2.1/i2.3 inversion 
6154R GCCTTTCAGCAGAATTCTAGCC i2.1/i2.3 deletion 
1861F TCTGTTAAAGCAGGCACATTGC 
2194F GTTTGATGCCAAGAAGGTAGCC i2.1/i2.2 inversion 




6673F AATTGCTCTGAGGCAGTGCTAA i2.1/i2.4 inversion 
6986R TGGAATTCTGAAGCAGACAAGAGA i2.1/i2.4 deletion 
1861F TCTGTTAAAGCAGGCACATTGC 
7377F TCTCCTAGTGGATTGTTTTGGCT i2.1/i2.6 inversion 
7915R TGTGCAGGCTTCAATCCATACT i2.1/i2.6 deletion 
1861F TCTGTTAAAGCAGGCACATTGC 
8209F TTTGCCATATCTTCTGCTGCTT i2.1/ex2-2.1 inversion 
7915R TGTGCAGGCTTCAATCCATACT i2.1/ex2-2.1 deletion 
2194F GTTTGATGCCAAGAAGGTAGCC 
7377F TCTCCTAGTGGATTGTTTTGGCT i2.2/i2.6 inversion 
7915R TGTGCAGGCTTCAATCCATACT i2.2/i2.6 deletion 
5698F AGTTGTATGAATGTGTGTGTGCC 
7377F TCTCCTAGTGGATTGTTTTGGCT i2.3/i2.6 inversion 
7915R TGTGCAGGCTTCAATCCATACT i2.3/i2.6 deletion 
6673F AATTGCTCTGAGGCAGTGCTAA 
7377F TCTCCTAGTGGATTGTTTTGGCT i2.4/i2.6 inversion 
7915R TGTGCAGGCTTCAATCCATACT i2.4/i2.6 deletion 
7377F TCTCCTAGTGGATTGTTTTGGCT 
8209F TTTGCCATATCTTCTGCTGCTT i2.6/ex2-2.1 inversion 
8710R GTGATCCGTCCTCACTGGC i2.6/ex2-2.1 deletion 
 
Table S3: List of primers used to amplify the duplications’ and inversions’ breakpoints. Primers used to amplify inversions 
in dup2 myoblasts are underlined in the present table.   
 
 
